vs

Side-by-side financial comparison of Atlanta Braves Holdings, Inc. (BATRA) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $61.3M, roughly 1.2× Atlanta Braves Holdings, Inc.). Atlanta Braves Holdings, Inc. runs the higher net margin — -67.6% vs -121.9%, a 54.3% gap on every dollar of revenue. On growth, Atlanta Braves Holdings, Inc. posted the faster year-over-year revenue change (17.6% vs -6.2%). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -52.5%).

Atlanta Braves Holdings, Inc. is a sports and entertainment holding company that owns and operates the Atlanta Braves MLB franchise. It also manages adjacent mixed-use real estate, live events, merchandise sales, and media operations, serving fans across the U.S. Southeast and global baseball audiences.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

BATRA vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.2× larger
HCAT
$74.7M
$61.3M
BATRA
Growing faster (revenue YoY)
BATRA
BATRA
+23.8% gap
BATRA
17.6%
-6.2%
HCAT
Higher net margin
BATRA
BATRA
54.3% more per $
BATRA
-67.6%
-121.9%
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-52.5%
BATRA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BATRA
BATRA
HCAT
HCAT
Revenue
$61.3M
$74.7M
Net Profit
$-41.4M
$-91.0M
Gross Margin
Operating Margin
-81.2%
-115.3%
Net Margin
-67.6%
-121.9%
Revenue YoY
17.6%
-6.2%
Net Profit YoY
-116.7%
-340.3%
EPS (diluted)
$-0.64
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BATRA
BATRA
HCAT
HCAT
Q4 25
$61.3M
$74.7M
Q3 25
$311.5M
$76.3M
Q2 25
$312.4M
$80.7M
Q1 25
$47.2M
$79.4M
Q4 24
$52.1M
$79.6M
Q3 24
$290.7M
$76.4M
Q2 24
$282.9M
$75.9M
Q1 24
$74.7M
Net Profit
BATRA
BATRA
HCAT
HCAT
Q4 25
$-41.4M
$-91.0M
Q3 25
$30.0M
$-22.2M
Q2 25
$29.5M
$-41.0M
Q1 25
$-41.4M
$-23.7M
Q4 24
$-19.1M
$-20.7M
Q3 24
$10.0M
$-14.7M
Q2 24
$29.1M
$-13.5M
Q1 24
$-20.6M
Gross Margin
BATRA
BATRA
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
BATRA
BATRA
HCAT
HCAT
Q4 25
-81.2%
-115.3%
Q3 25
12.5%
-22.9%
Q2 25
13.4%
-46.0%
Q1 25
-94.2%
-25.4%
Q4 24
-35.8%
-22.0%
Q3 24
2.2%
-17.9%
Q2 24
8.8%
-20.8%
Q1 24
-30.5%
Net Margin
BATRA
BATRA
HCAT
HCAT
Q4 25
-67.6%
-121.9%
Q3 25
9.6%
-29.1%
Q2 25
9.4%
-50.8%
Q1 25
-87.7%
-29.9%
Q4 24
-36.7%
-26.0%
Q3 24
3.4%
-19.3%
Q2 24
10.3%
-17.8%
Q1 24
-27.6%
EPS (diluted)
BATRA
BATRA
HCAT
HCAT
Q4 25
$-0.64
$-1.29
Q3 25
$0.47
$-0.32
Q2 25
$0.46
$-0.59
Q1 25
$-0.66
$-0.35
Q4 24
$-0.29
$-0.33
Q3 24
$0.16
$-0.24
Q2 24
$0.46
$-0.23
Q1 24
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BATRA
BATRA
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$99.9M
$95.7M
Total DebtLower is stronger
$738.6M
$153.3M
Stockholders' EquityBook value
$526.0M
$245.8M
Total Assets
$1.6B
$502.6M
Debt / EquityLower = less leverage
1.40×
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BATRA
BATRA
HCAT
HCAT
Q4 25
$99.9M
$95.7M
Q3 25
$82.2M
$91.5M
Q2 25
$96.2M
$97.3M
Q1 25
$244.7M
$342.0M
Q4 24
$110.1M
$392.0M
Q3 24
$100.9M
$387.3M
Q2 24
$121.2M
$308.3M
Q1 24
$327.8M
Total Debt
BATRA
BATRA
HCAT
HCAT
Q4 25
$738.6M
$153.3M
Q3 25
$759.9M
$153.1M
Q2 25
$703.1M
$153.0M
Q1 25
$699.5M
$382.9M
Q4 24
$617.1M
$382.4M
Q3 24
$640.1M
$345.0M
Q2 24
$600.0M
Q1 24
Stockholders' Equity
BATRA
BATRA
HCAT
HCAT
Q4 25
$526.0M
$245.8M
Q3 25
$560.3M
$331.9M
Q2 25
$522.8M
$347.5M
Q1 25
$486.1M
$376.8M
Q4 24
$524.2M
$365.2M
Q3 24
$530.4M
$355.0M
Q2 24
$512.7M
$357.0M
Q1 24
$357.2M
Total Assets
BATRA
BATRA
HCAT
HCAT
Q4 25
$1.6B
$502.6M
Q3 25
$1.7B
$587.1M
Q2 25
$1.7B
$616.2M
Q1 25
$1.7B
$891.5M
Q4 24
$1.5B
$858.9M
Q3 24
$1.6B
$813.0M
Q2 24
$1.6B
$691.7M
Q1 24
$695.1M
Debt / Equity
BATRA
BATRA
HCAT
HCAT
Q4 25
1.40×
0.62×
Q3 25
1.36×
0.46×
Q2 25
1.34×
0.44×
Q1 25
1.44×
1.02×
Q4 24
1.18×
1.05×
Q3 24
1.21×
0.97×
Q2 24
1.17×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BATRA
BATRA
HCAT
HCAT
Operating Cash FlowLast quarter
$26.4M
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.0%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BATRA
BATRA
HCAT
HCAT
Q4 25
$26.4M
$9.9M
Q3 25
$-88.8M
$-464.0K
Q2 25
$-8.1M
$-9.0M
Q1 25
$95.8M
$280.0K
Q4 24
$28.9M
$-3.5M
Q3 24
$-69.0M
$6.2M
Q2 24
$-34.3M
$1.6M
Q1 24
$10.3M
Free Cash Flow
BATRA
BATRA
HCAT
HCAT
Q4 25
$9.6M
Q3 25
$-719.0K
Q2 25
$-82.3M
$-9.2M
Q1 25
$76.3M
$-390.0K
Q4 24
$16.8M
$-3.9M
Q3 24
$-85.5M
$5.5M
Q2 24
$-64.1M
$1.3M
Q1 24
$10.1M
FCF Margin
BATRA
BATRA
HCAT
HCAT
Q4 25
12.9%
Q3 25
-0.9%
Q2 25
-26.3%
-11.4%
Q1 25
161.5%
-0.5%
Q4 24
32.3%
-4.9%
Q3 24
-29.4%
7.2%
Q2 24
-22.7%
1.7%
Q1 24
13.5%
Capex Intensity
BATRA
BATRA
HCAT
HCAT
Q4 25
0.0%
0.4%
Q3 25
0.0%
0.3%
Q2 25
23.7%
0.3%
Q1 25
41.3%
0.8%
Q4 24
23.2%
0.5%
Q3 24
5.7%
0.9%
Q2 24
10.5%
0.4%
Q1 24
0.3%
Cash Conversion
BATRA
BATRA
HCAT
HCAT
Q4 25
Q3 25
-2.96×
Q2 25
-0.28×
Q1 25
Q4 24
Q3 24
-6.89×
Q2 24
-1.18×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BATRA
BATRA

Baseball$34.8M57%
Mixed Use Development Segment$26.5M43%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons